Idorsia (IDIA) Company Presentation summary

Business overview and strategy

• Experienced team with a proven track record and three approved drugs since 2017, including QUVIVIQ and TRYVIO/JERAYGO.

• Focus on advancing a prioritized, science-driven pipeline and leveraging strategic partnerships.

• Commercial trajectory driven by QUVIVIQ expansion and pipeline assets with blockbuster potential.

• Strong financial position with profitability targeted by end of 2027.

• Capital allocation prioritizes high-impact, differentiated assets and commercial reach.

Financial performance and outlook

• Revenue projected to grow from CHF 32m in 2023 to CHF 130m in 2025, with OPEX stabilized at CHF 290m.

• Liquidity of CHF 207m extends cash runway into 2028; market capitalization at CHF 787m as of Nov 2025.

• Commercial profitability expected in 2026, with overall profitability by Q4 2027.

• Debt restructured in an asset-backed vehicle, with long-term value upon repayment.

• Additional income streams anticipated from partnerships and royalties.

Product portfolio and pipeline

• QUVIVIQ (daridorexant) shows strong global sales and is available in major markets; best-in-class profile for insomnia.

• TRYVIO (aprocitentan) is the first innovation in hypertension in 30 years, targeting difficult-to-control cases.

• Lucerastat offers a novel oral therapy for Fabry disease, with potential to preserve kidney function.

• Multiple first-in-class assets in late-stage development, including selatogrel and cenerimod.

• Pediatric insomnia study for daridorexant ongoing, with results expected in Q2 2026.